Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,374 across all filing types
Latest filing 2022-01-13 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCED PHASE II GEMSTONE-201 TRIAL OF CEJEMLY (SUGEMALIMAB) MET PRIMARY ENDPOINT OF OBJECTIVE RESPONSE RATE (ORR) IN PATIENTS WITH RELAPSED OR REFRACTORY EXTRANODAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals regarding the successful results of a Phase II clinical trial (GEMSTONE-201) for their drug Cejemly (sugemalimab) in treating relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL). It discusses clinical trial outcomes, regulatory designations, and future plans for drug application submission. There are no financial statements, regulatory certifications, or detailed financial data. The document is an announcement of clinical trial results and future regulatory plans, not a financial report or regulatory filing. It is not an earnings release or investor presentation but a voluntary announcement about clinical progress and regulatory status. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-01-13 English
Documents on Display
Capital/Financing Update Classification · 95% confidence The document is a short announcement from Yankuang Energy Group Company Limited regarding the 'Proposed Adoption of the Restricted A Share Incentive Scheme' and a 'Connected Transaction'. It provides links to external PDF files (Circular, Incentive Scheme draft, and a consent letter) rather than containing the full content of those reports itself. Given the short length (893 characters) and the nature of the text as a notification of published materials, it falls under the Report Publication Announcement (RPA) category.
2022-01-12 English
Notification Letter
Report Publication Announcement Classification · 100% confidence The document is a notification letter from Yankuang Energy Group Company Limited dated 12 January 2022. It informs shareholders about the publication of the circular for the 2022 First Extraordinary General Meeting (EGM). The letter provides instructions on how shareholders can access the circular electronically or request printed copies, and includes a change request form for shareholders to update their preferences for receiving corporate communications. The document does not contain the circular itself, financial data, or detailed meeting materials, but rather serves as a notice of publication and instructions related to corporate communications. According to the classification rules, such a document is an announcement regarding the publication of a report or circular, not the report itself. Therefore, it fits the category of Report Publication Announcement (RPA).
2022-01-12 English
Circular
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed circular from Yankuang Energy Group Company Limited regarding the proposed adoption of a Restricted A Share Incentive Scheme and connected transactions related to granting restricted shares to connected participants. It includes definitions, letters from the board, independent board committee, and independent financial adviser, and appendices related to the incentive scheme. The document is intended for shareholders to inform them about the proposal and related matters ahead of an Extraordinary General Meeting (EGM) and class meetings. This type of document is a proxy solicitation and information statement, as it provides information to shareholders to solicit their votes on specific proposals at a meeting. It is not an annual report, earnings release, or other financial report, nor is it a simple announcement or regulatory filing. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI). The document length (15,000 characters) and content confirm it is a full circular, not just an announcement or notice.
2022-01-12 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2021
Regulatory Filings Classification · 95% confidence The document is a detailed monthly report on movements in securities, specifically focusing on the authorized and issued share capital, share options, and other share-related movements for CStone Pharmaceuticals. It includes data on share capital changes, share options exercised or lapsed, and confirmations related to the issuance of securities. The document is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules. It is not an annual or quarterly financial report, nor is it an earnings release or management discussion. It is a regulatory filing related to share capital movements and confirmations, which fits the category of Regulatory Filings (RNS) as it does not fall under more specific categories like Share Issue/Capital Change (SHA) because it is a monthly return report rather than a single announcement of a capital change event. The document length and detail confirm it is a substantive regulatory filing rather than a brief announcement or certification.
2022-01-06 English
Monthly Returns
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 December 2021. It details movements in authorised/registered share capital, issued shares, share options, and confirms no new securities were issued during the month. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting share capital and share movements for a specific month. It does not contain financial statements, earnings data, management discussion, or audit information. It is a periodic regulatory filing about share capital and securities movements, fitting the category of Regulatory Filings (RNS) as it does not match other more specific categories like Share Issue/Capital Change (SHA) because no new shares were issued or capital changed during the month, and it is not a report publication announcement or certification. Therefore, the best classification is Regulatory Filings (RNS).
2022-01-04 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.